Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Exclusion Criteria

• •Myocardial infarction,coronary artery bypass graft surgery, or other major cardiovascular surgery within 30 days after enrollment
• •Percutaneous coronary intervention ,coronary artery bypass graft surgery,cardiac resynchronization therapy, implantable cardioverter defibrillatoror or other cardiac surgeries within 90 days prior to enrollment
• •Atrial fibrillation or flutter
• •SGLT-2i using within 90 days prior to enrollment
• •Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease),cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), or known pericardial constriction
• •Acute decompensated heart failure.
• •Moderate to severe valvular stenosis or regurgitation
• •Symptomatic hypotension with systolic pressure ≤ 90mmHg or uncontrolled hypertension using drugs with systolic blood pressure of ≥180 mmHg at randomization
• •Sever infectious diseases(e.g. Severe myocarditis, severe pneumonia, and severe urinary tract infection)
• •Chronic pulmonary disease requiring home oxygen, oral corticosteroid therapy or hospitalization for exacerbation within 12 months
• •Other significant co-morbid conditions(impaired renal function( an estimated glomerular filtration rate of \<20 mL/min/1.73 m2), hepatic failure, malignant tumors, severe hematologic diseases, etc.)
• •Major surgery performed within 90 days prior to enrollment or major scheduled elective surgery within 90 days after enrollment(major according to the investigator's assessment,such as gastrointestinal surgery that might interfere with trial medication absorption or malignant tumors surgery)
• •Type 1 diabetes or history of ketoacidosis
• •Pregnancy
• •Completion within 90 days of a trial of another drug study. Receipt of any investigative treatment other than the study medications for this trial